We are a research and development company. Our objective is to cure insulin-requiring diabetes by means of a thin-sheet bio-artificial pancreas.

View a brief presentation of the Islet Sheet Technology narrated by Scott King.

View our interactive overview of our work on a cure for diabetes [requires Macromedia Flash plugin]

Diabetes: The Search for a Cure

Our web site has information on this company, our research and development on the cure for diabetes, and the science of our thin-sheet bio-artificial pancreas.

You can click here and sign up for our e-mail news.

April 18, 2010
"Islet Sheet Technology-Hope for Diabetes Cure"
President of Cerco Medical is interviewed on leading diabetes blog site

HONG KONG - Scott King, pioneer diabetes biotechnology analyst, and founding President of Cerco Medical, is determined to find a cure for diabetes.

More specifically, Scott is leading the development of a new technology that will provide stable blood glucose levels without injected insulin or immunosuppressive drugs. The technology is based on a removable, bio-invisible sheet called an Islet Sheet and research is ongoing now at the University of California, Irvine (UCI). The research project’s name is the Solving Diabetes Project, and funding is provided by the Hanuman Medical Foundation.

Click for entire interview.

April 5, 2010
Diabetes Research Awarded

U.C. Discovery Grant

SAN FRANCISCO, CALIFORNIA - University of California - Irvine researcher Jonathan Lakey, PhD, has been awarded a UC Discovery grant. The Discovery grant recognizes highly meritorious research that addresses California's needs and is extremely competitive. Hanuman Medical Foundation, a San Francisco non-profit organization that supports innovative research, has added funds, bringing the total grant for Dr. Lakey’s research to $105,000.

The proposal, Islet Transplantation Using Alginate Sheet, is a collaboration with San Francisco-based Cerco Medical......

Click for entire article.

October 26, 2009
Cerco Medical and UC Irvine announce a new Publication:
Islet transplantation using Macroencapsulation device

SAN FRANCISCO, CALIFORNIA - Cerco Medical, a privately held research company, and the University of California - Irvine have published another paper stemming from their new collaboration. The paper, "Islet transplantation using Macroencapsulation device," was presented at the October, 2009 joint meeting of the International Pancreas and Islet Transplantation Association and the International Xenotransplantation Association in Venice, Italy.

July 1, 2009
Cerco Medical Collaborates with University of California Irvine
on Diabetes Therapy

SAN FRANCISCO, CALIFORNIA - Cerco Medical has reached agreement with the University of California to sponsor research on the company's proprietary thin sheet bioartificial pancreas to treat diabetes. The University's lead researcher is Jonathan R. T. Lakey, Associate Professor and Director of Research in the Department of Surgery at the Medical School on the Irvine Campus.

Cerco Medical has invented and patented a thin alginate sheet to protect transplanted islets without immune suppression drugs. The Islet Sheet responds to changing blood sugar levels with the release of insulin in real time, mimicking the normal function of pancreatic islets. The Islet Sheet consists of live, functional islets contained within an immunologically protective coating made from a hydrogel polymer called alginate derived from kelp.

Scott King, President of Cerco Medical, commented, "We are ......

Click for entire article.

April 21, 2009

Lux Research, which provides strategic advice and on-going intelligence for emerging technologies, today published a report on Cerco Medical LLC. Their take on the Islet Sheet is that it is an unmatched 'intriguing alternative to immunosupressant regimen or microencapsulated islets' and that their clients should monitor progress for licensing opportunity.'

Scott King, President of Cerco Medical, commented "This is the first published report on Cerco Medical since we restarted research, and we are please to see that it is positive."

Click for more news.

April 8, 2009
Cerco Medical and UC Irvine announce First Publication:
Biopolymer selected for bioartifical pancreas device studies

SAN FRANCISCO, CALIFORNIA - Cerco Medical, a privately held research company, and the University of California - Irvine have published their first paper stemming from their new collaboration. The paper, "Host response to alginate sheets: effect of alginate source," was presented at the March, 2009 Rachmiel Levine Diabetes Symposium sponsored by the Southern California Islet Cell Resources (SC-ICR) Center at the City of Hope.

The joint project is for the development of the Islet Sheet, an implantable device designed to deliver the metabolic advantages of islet transplantation without the use of immune suppression drugs. The Islet Sheet promises to be an important new therapy for type 1 diabetes.

The paper compares various sources of alginate, a biopolymer derived from seaweed. As the paper shows, one of the alginates made by Cerco Medical has been selected to be used in further investigations.

The funding for this research is coming from the Hanuman Medical Foundation and the UC-Irvine Department of Surgery.

September 2, 2008
Cerco Medical begins research with the University of California, Irvine
With the recent appointment of Jonathan Lakey as Director of Research in the Department of Surgury at the UC Irvine Medical Center in Orange, CA, Cerco Medical has revived research on the Islet Sheet. Click here to read more about this collaboration.